A New Predictor for Insulin Resistance in Polycystic Ovary Syndrome: InsuTAG

Basit Öğe Kaydı
dc.authoridGökçe, Aksanur/0000-0001-8547-6523
dc.authoridOmma, Tülay/0000-0002-2557-9499
dc.authoridKarahan, İrfan/0000-0003-4669-1751
dc.contributor.authorOmma, Tülay
dc.contributor.authorGökçe, Aksanur
dc.contributor.authorÇelik, Mustafa
dc.contributor.authorKarahan, İrfan
dc.contributor.authorÇulha, Cavit
dc.contributor.authorGülçelik, Neşe Ersöz
dc.date.accessioned2025-01-21T16:35:07Z
dc.date.available2025-01-21T16:35:07Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women of reproductive age. PCOS leads to metabolic dysfunction such as dyslipidemia, obesity, and glucose intolerance based on hyperandrogenemia, hyperinsulinemia, and dysregulated adipokine secretion.Objective: The aim of this study was to investigate whether a new marker, InsuTAG (fasting insulinxfasting triglycerides) could predict insulin resistance (IR) in patients of PCOS.Methods: In this study, retrospective data of 300 female patients diagnosed with PCOS were analyzed. The relationship between InsuTAG and HOMA-IR, TyG, and TG/HDL-C scores related to insulin resistance was evaluated. In addition, the distribution of the cases according to the cut-off values was determined.Results: Log-transformed forms of InsuTAG and HOMA-IR, TyG and TG/HDL-C results were positively correlated, respectively. (r = 0.85, p < 0.001; r = 0.78, p < 0.001; r = 0.72, p < 0.001). Sensitivity, specificity, positive predictive value and negative predictive values for InsuTAG were calculated as 85%, 85%, 82% and 88%, respectively.Conclusion: This study is the first to compare the InsuTAG, another predictor of insulin resistance, with other IR markers in women with PCOS. InsuTAG is a novel biomarker based on plasma sampling of insulin and triglyceride, with minimally invasive, inexpensive and orientally accessible features.
dc.description.sponsorshipWe thank all of our patients in our study.
dc.description.sponsorshipWe thank all of our patients in our study.
dc.identifier.doi10.2174/1573404820666230301115706
dc.identifier.issn1573-4048
dc.identifier.issn1875-6581
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85177468347
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.2174/1573404820666230301115706
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24080
dc.identifier.volume20
dc.identifier.wosWOS:001058676500012
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Womens Health Reviews
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectPolycystic ovary syndrome; triglyceride; hyperlipidemia; high-density lipoprotein; insulin resistance; obesity
dc.titleA New Predictor for Insulin Resistance in Polycystic Ovary Syndrome: InsuTAG
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu